Compare Jumia Technologies AG - ADR (JMIA) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jumia Technologies AG - ADR vs Tempus AI — how do they compare? Jumia Technologies AG - ADR trades at $6.53 (market cap $900.64M), while Tempus AI trades at $70.48 (market cap $12.77B). The key difference: Tempus AI is far larger — about 14.2× Jumia Technologies AG - ADR's market cap, and Tempus AI is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Jumia Technologies AG - ADR for 28 Days and Tempus AI for 22 Days on average.
| JMIA | TEM | |
|---|---|---|
Market Cap | $900.64M | $12.77B |
Volume | 625,675 | 8,980,490 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $14.60 | $99.28 |
52-Week Low | $5.69 | $41.55 |
Typical Hold Time | 28 Days | 22 Days |
Enterprise Value | $866.28M | $13.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JMIA trades at $6.74, down 0.88% with bearish technical signals. The company shows improving fundamentals with revenue growth to $189M in 2025 and narrowing losses (-$62M net income). Recent $50M capital injection from IFC strengthens the balance sheet while management targets EBITDA breakeven by Q4 2026. Analyst consensus remains bullish with $12 price target despite recent earnings misses.
JMIA presents a turnaround story with operational improvements and path to profitability, but carries significant execution risk. The stock offers substantial upside to analyst targets if the company achieves its breakeven timeline, though persistent losses and competitive pressures remain concerns for investors.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
